A perspective article published in Cardiology Discovery addresses a persistent real‑world “risk‑treatment paradox” for patients with non‑ST‑segment elevation myocardial infarction (NSTEMI, a common type of heart attack): patients at the highest predicted risk frequently fail to receive guideline‑endorsed early invasive therapy, even though registry data link invasive care to lower in‑hospital mortality. Authors Yong Hoon Kim and Ae‑Young Her propose moving beyond simple risk‑score thresholds toward multidimensional, patient‑centered decision‑making for invasive angiography and revascularization.
Current European Society of Cardiology and American College of Cardiology/American Heart Association guidelines use risk stratification to set timing for invasive procedures in NSTEMI. In routine practice, however, clinicians often withhold early invasive intervention from high‑risk patients out of concern for procedural hazards. Large‑scale registries underscore this gap: one UK national analysis of 137,265 NSTEMI patients treated between 2010 and 2015 found that a guideline‑aligned invasive strategy was delivered within the recommended time window to merely 16.4% of high‑risk individuals. A United States registry analysis of 287,275 patients similarly showed that older patients with more comorbidities — a higher‑risk group — were less likely to receive timely invasive care, even though propensity‑weighted data showed invasive therapy correlated with lower in‑hospital mortality (weighted odds ratio: 0.36; 95% confidence interval: 0.31‑0.42). Because these registry findings are observational, this association is subject to confounding by indication and does not establish causation. System‑level barriers including limited after‑hours catheter‑lab access also contribute to care disparities.
This work is a narrative perspective synthesizing published registry datasets, randomized clinical trial results and pathophysiological evidence rather than original primary data. Authors re‑examined landmark trials underpinning existing guideline timing recommendations, pointing out key limitations: older studies used older‑generation stents and had low percutaneous coronary intervention (PCI) rates that may not reflect modern clinical workflows. They also reviewed evidence showing approximately one‑quarter of NSTEMI patients have a totally occluded culprit coronary artery — lesions functionally similar to ST‑segment elevation myocardial infarction despite the absence of diagnostic electrocardiogram changes.
Several key clinical observations emerge from the synthesized evidence. The Global Registry of Acute Coronary Events (GRACE) score predicts event risk but cannot fully quantify the net clinical benefit of an invasive strategy; high scores driven by advanced age or kidney disease come with elevated procedural risk that may offset potential gains. Conversely, younger patients with ongoing ischemia or rapidly rising troponin may gain substantial benefit from early angiography despite moderate GRACE scores. Authors advocate reframing clinical questions from “should we do angiography?” toward “when should we perform angiography?”, integrating ischemic burden, frailty, bleeding risk, renal function and patient preferences alongside risk scores. They also note system‑wide quality‑improvement measures, modeled on established ST‑elevation myocardial infarction regional networks, could reduce off‑hours care gaps. “Risk scores should tell us when to take a patient to the catheterization laboratory, not whether to take them at all,” said corresponding author Yong Hoon Kim of Kangwon National University College of Medicine. “The patients who stand to gain the most are too often the ones we hesitate to treat.”
Important limitations temper these recommendations. As a narrative perspective, it does not generate new primary clinical trial data. Existing randomized evidence for optimal timing draws from older patient cohorts and device eras. Therefore, contemporary randomized controlled trials using modern stents and pharmacotherapy are required to validate ideal angiography timing thresholds for today’s NSTEMI populations. Until new trial data become available, clinicians should adopt a multidimensional assessment and favor earlier angiography when ischemic risk outweighs procedural hazards.
Article citation
Published in Cardiology Discovery , DOI: 10.1097/CD9.0000000000000206
Cardiology Discovery
Commentary/editorial
Not applicable
Early Invasive Strategy in Non-ST-Segment Elevation Myocardial Infarction: Beyond the High-Risk Label
31-Jul-2026